Multiparametic MRI findings may help decrease false-positive prostate biopsy results and reduce the number of unnecessary biopsies, reports Renal and Urology News.

At a risk threshold of 20%, the MRI-based model had a lower false-positive rate than the baseline model (46% vs 92%), with only a small reduction in the true-positive rate (89% vs 99%), a team led by by Baris Turkbey, MD, of the National Cancer Institute (NCI) in Bethesda, Maryland, reported online ahead of print in JAMA Oncology. At a 20% risk cutoff, 38% of biopsies could have been avoided with the MRI model compared with 6% of biopsies avoided by the baseline model.

“The net reduction in the number of false-positives based on the MRI model, compared with having to perform a biopsy in all patients with positive MRI results, was equivalent to performing 18 fewer unnecessary biopsies per 100 men, with no increase in the number of clinically significant prostate cancer left undiagnosed,” the investigators stated.